（3-三苯基甲氨基甲基）吡啶 | 918311-87-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: （3-三苯基甲氨基甲基）吡啶
• 中文别名: N-三苯甲基-3-吡啶甲胺
• 英文名称: UCL2077
• 英文别名: (3-Triphenylmethylaminomethyl)pyridine；1,1,1-triphenyl-N-(pyridin-3-ylmethyl)methanamine
• CAS: 918311-87-2
• 化学式: C₂₅H₂₂N₂
• 分子量: 350.463
• InChiKey: PQFNWDHABGBCHB-UHFFFAOYSA-N

物化性质

• 溶解度：
  在DMSO中的溶解度>20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

制备方法与用途

生物活性

UCL 2077是sAHP通道的选择性抑制剂，在海马神经元中的半数有效浓度（IC50）为500 nM。它对Ca²⁺通道、动作电位、输入电阻以及超极化后的介质影响较小。此外，UCL 2077也是亚型选择性的癫痫相关KCNQ通道的阻滞剂。

靶点

sAHP.

反应信息

• 作为产物：
  描述：

  3-氨甲基吡啶 、 三苯基甲醇 在 三异丙氧基氧化钒 作用下， 以 乙腈 为溶剂， 以97 %的产率得到（3-三苯基甲氨基甲基）吡啶
  参考文献：
  名称：

  钒催化α-三芳基醇的直接胺化

  摘要：

  α-三芳基胺已被用作抗真菌和抗癌应用的药物和药物中间体。目前合成此类化合物的方法至少需要两步，并且没有报道过直接胺化叔醇。在此，我们公开了直接胺化 α-三芳基醇以获得 α-三芳基胺的有效催化条件。VO(O i Pr) 3，一种市售试剂，已被确定为几种α-三芳基醇直接胺化的有效催化剂。这个过程是可扩展的，正如克级合成所证明的那样，反应在低至 0.01 mol% 的催化剂负载下仍然有效，周转数达到 3900。此外，包括克霉唑和氟霉唑在内的商业药物已成功快速制备，有效地使用这种新开发的方法。

  DOI：

  10.1021/acs.joc.3c00414

文献信息

• Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US11221329B2

  公开（公告）日：2022-01-11

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

  本发明提供了用于治疗和/或减轻神经或神经发育疾病或紊乱症状的方法，该疾病或紊乱的特征是某些离子通道的异位表达，特别是 Nav1.8 亚型 SCN10a 钠通道或 KCNQ1 钾通道在中枢神经系统（CNS）神经细胞中的异位表达。8亚型SCN10a钠通道或KCNQ1钾通道的方法，该方法通过向有需要的受试者施用一种或两种这些离子通道的拮抗剂，特别是SCN10a的拮抗剂，以阻断、减少或抑制异常的中枢神经系统（CNS）离子通道、或抑制异常的中枢神经系统神经元离子通道表达和/或活性，使与神经系统和神经发育疾病或紊乱相关的行为和认知缺陷正常化，从而治疗和/或减轻神经系统或神经发育疾病或紊乱的症状。可通过所述方法治疗的此类疾病或紊乱的例子包括皮特-霍普金斯综合征（PTHS）、自闭症、自闭症谱系障碍、精神分裂症、18q 综合征等。
• Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US20180328915A1

  公开（公告）日：2018-11-15

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.
• [EN] TREATMENT OF NEUROLOGICAL AND NEURODEVELOPMENTAL DISEASES AND DISORDERS ASSOCIATED WITH ABERRANT ION CHANNEL EXPRESSION AND ACTIVITY<br/>[FR] TRAITEMENT DE MALADIES ET DE TROUBLES NEUROLOGIQUES ET NEURDÉVELOPPEMENTAUX ASSOCIÉS À UNE EXPRESSION ET À UNE ACTIVITÉ ABERRANTE DES CANAUX IONIQUES
  申请人：LIEBER INST FOR BRAIN DEV

  公开号：WO2017075222A1

  公开（公告）日：2017-05-04

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.
• Direct Amination of α-Triaryl Alcohols via Vanadium Catalysis
  作者：Jinglei Yang、Yun-Dong Wu、Maoping Pu

  DOI：10.1021/acs.joc.3c00414

  日期：2023.6.2

  α-Triaryl amines have been used as pharmaceuticals and pharmaceutical intermediates for antifungal and anticancer applications. Current methods to synthesize such compounds require at least two steps, and no direct amination of tertiary alcohols has been reported. Herein, we disclose efficient catalytic conditions for the direct amination of α-triaryl alcohols to access α-triaryl amines. VO(OiPr)3

  α-三芳基胺已被用作抗真菌和抗癌应用的药物和药物中间体。目前合成此类化合物的方法至少需要两步，并且没有报道过直接胺化叔醇。在此，我们公开了直接胺化 α-三芳基醇以获得 α-三芳基胺的有效催化条件。VO(O i Pr) 3，一种市售试剂，已被确定为几种α-三芳基醇直接胺化的有效催化剂。这个过程是可扩展的，正如克级合成所证明的那样，反应在低至 0.01 mol% 的催化剂负载下仍然有效，周转数达到 3900。此外，包括克霉唑和氟霉唑在内的商业药物已成功快速制备，有效地使用这种新开发的方法。